SCHEMBL2636741

SCHEMBL2636741

CC(=O)N(C)C1CN(c2ccc(C(N)=O)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.48
CHRNA7 P36544 1/20 0.43
CHRNA10 Q9GZZ6 1/20 0.43
CHRNA9 Q9UGM1 1/20 0.43
SYK P43405 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
CHEK1 O14757 1/20 0.39
MAP4K4 O95819 1/20 0.38
ACVR1 Q04771 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
NOS1 P29475 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636123 0.89 MCHR1 (0.61) MCHR1CHRNA7CHRNA10CHRNA9SYK
SCHEMBL1749513 0.84 GFER (0.49) MCHR1SYKMAP4K4MEN1ALDH1A1
SCHEMBL4287740 0.78 MCHR1 (0.58) MCHR1CHRNA7CHRNA10CHRNA9GPR119
SCHEMBL2636306 0.78 MCHR1 (0.58) MCHR1CHRNA7CHRNA10CHRNA9GPR119
SCHEMBL1749899 0.77 MAPT (0.48) MEN1ALDH1A1KMT2AMAPT
SCHEMBL25629582 0.75 CHRNA7 (0.47) CHRNA7CHRNA10CHRNA9GPR119CHEK1
SCHEMBL1750857 0.74 MCHR1 (0.58) MCHR1SYKMAP4K4HRH3CCNC
SCHEMBL1749414 0.74 MCHR1 (0.58) MCHR1SYKMAP4K4HRH3CCNC
SCHEMBL1750259 0.74 MCHR1 (0.58) MCHR1SYKMAP4K4HRH3CCNC
SCHEMBL2636418 0.73 MCHR1 (0.47) MCHR1CHRNA7CHRNA10CHRNA9GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220191-A1 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments CYP11B2, CYP11B1, CYP1A1 MCHR1 1838/4885CHRNA7 2988/4885CHRNA10 3997/4885
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885CHRNA7 2830/4885CHRNA10 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.